ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Ò©ÎïתÔËÌåÊÇλÓÚϸ°ûĤÉϵÄÖ÷ÒªµÄ¹¦Ð§ÐÔĤÂѰף¬ÊÇÒ©Îï¿çϸ°ûĤתÔ˵ÄÔØÌ壬ÔÚÒ©ÎïÎüÊÕ,ÂþÑÜ,´úл¼°ÉøÍ¸µÈÒ©´ú¶¯Á¦Ñ§Àú³ÌÖÐʩչÖ÷Òª×÷Óá£Õؽ¨Ö®³õ£¬×ðÁú¿Ê±¼´×¢ÖØ´òÔìһվʽЧÀÍ£¬ÖÂÁ¦ÓÚΪ¿Í»§½ÚԼʱ¼ä±¾Ç®£¬Ìá¸ßÏàͬЧÂʽø¶ø¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£»ÏÖÔÚ£¬ÔÚÒ»Ö±ÍêÉÆÒ»Õ¾Ê½Ð§À͵Äͬʱ£¬×ðÁú¿Ê±Ç±ÐÄרעµÄÒ»Ö±ÌáÉýƽ̨רҵˮƽ£¬ÒÔÆÚΪ¿Í»§ÌṩÖÜȫϸ»¯£¬Ô½·¢¾«×¼ÉîÈëµÄЧÀÍ¡£Ò©ÎïתÔËÌåµÄÑо¿×÷Ϊ×ðÁú¿Ê±Ï¸»¯Ð§ÀÍϵͳÖеÄÒ»Ïî³ÉÊìÊÖÒÕ¿ÉÒÔΪÐÂÒ©Éè¼Æ¡¢Ìá¸ßÒ©Îï°ÐÏòÐÔ¼°Ò©ÎïÏ໥×÷ÓõÈÑо¿Ìṩ¿É¿¿ÒÀ¾Ý¡£
CFDA¡¶Ò©Îï·ÇÁÙ´²Ò©´ú¶¯Á¦Ñ§Ñо¿ÊÖÒÕÖ¸µ¼ÔÔò¡·ÓëFDA¡¶Ò©ÎïÏ໥×÷ÓÃÑо¿ÊÖÒÕÖ¸µ¼ÔÔò(²Ý°¸)(Drug Interaction Studies¡ªStudy Design,Data Analysis, and Implications for Dosing and Labeling Recommendations Draft Guidance for Industry)¹«²¼ÒÔÀ´£¬ÆßÖÖ¾ßÓÐÖ÷ÒªÁÙ´²ÒâÒåµÄÍâÅźÍÉãÈëתÔËÌ壨P-gp¡¢BCRP¡¢OATP1B1¡¢OATP13¡¢OAT1¡¢OAT3ºÍOCT2£©ÔÚÒ©´ú¶¯Á¦Ñ§Àú³ÌÖеÄ×÷ÓÃÕýÈÕÒæ³ÉΪÁ¢ÒìÐÂÒ©ÎïÑо¿ÓëÉ걨µÄ±Ø±¸Ñо¿ÏîÄ¿¡£×ðÁú¿Ê±Ò©ÎïתÔËÌåÑо¿ÍŶÓÒµÒѽ¨Éè¶ÔÕâЩÖ÷ҪתÔËÌåµÄ³ÉÊìÌåÍâÑо¿ÊÖÒÕ¡£Í¨¹ý¹¹½¨¸üÎȹ̵ÄÌåÍâϸ°ûÄ£×Ó²¢¾ÙÐиüÑϽ÷µÄÑéÖ¤£¬×ðÁú¿Ê±½«¸ü׼ȷ¡¢¸ü¿ìËÙµÄΪҵ½çͬÈÊÌṩÓÅÖʵÄתÔËÌåÑо¿Ð§ÀÍ¡£
¡øÒ©ÎïתÔËÌåÔÚÒ©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úл¡¢ÉøÍ¸ÖеÄ×÷ÓÃ
ʲôÊÇÒ©ÎïתÔËÌ壿
Ò©ÎïתÔËÌåÊÇһϵÁб£´æÓÚϸ°ûĤÍâò£¬¼ÌÐøÒ©Îï¿çĤתÔ˹¦Ð§µÄÂѰ×ÖʵÄ×ܳơ£ËüÃǼÓÈëÒ©Îï½øÈëÉúÎïÌåµÄÎüÊÕÀú³Ì£¬µ÷¿ØÒ©Îï´©Ô½ÉúÎïÆÁÕϵÄÌåÄÚÂþÑÜÀú³Ì£¬×îÖս鵼¸ÎÔàºÍÉöÔà¶ÔÒ©Îï¼°Æä´úл²úÆ·µÄÉøÍ¸¡£´ó´ó¶¼µÍÖ¬ÈÜÐÔ¡¢Ð¡·Ö×ÓÁ¿µÄÒ©ÎÆä·Ö×ÓÒòËØ¿Éͨ¹ý´¿´âÀ©É¢ÐÎʽ͸Ï꾡°ûµÄË«²ãÁ×֬Ĥ£¬¶øÖ¬ÈÜÐԵ͡¢·Ö×ÓÁ¿½Ï´óµÄ¼«ÐÔÒ©Îͨ³£ÒÔתÔËÌåΪǰÑÔʵÏÖ¿çϸ°ûĤתÔË¡£
¡øÒ©ÎïתÔËÌåµÄÁ½´óÀàÐÍ
Ò©ÎïתÔËÌåµÄÖÖÀà
ÈËÌåÄÚ¼ÓÈëÒ©Îï¿çĤµÄתÔËÌåÖÖÀàÖڶ࣬°´¿çĤתÔËÆ«Ïò¿É·ÖΪÉãÈëºÍÍâÅÅÁ½´óÀà¡£½éµ¼Ò©Îï½øÈëϸ°ûµÄÉãÈëתÔËÌåÊôÓÚÈÜÖÊÔØÌåÂѰ×(solute carrier,SLC)¼Ò×壬Ö÷Òª°üÀ¨°±»ùËáתÔËÌå(L-type amino transporter, LAT)¡¢ÄÆÒÀÀµÐÔÐø·¢ÐÔ×Ô¶¯×ªÔËÌå (sodium dependent secondary activetransporters, SGLTs)¡¢ÓлúÒõÀë×Ó (organic anion transporters, OATs)¼°ÑôÀë×ÓתÔËÌå(organic cation transporters, OCTs)µÈ¡£ÍâÅÅתÔËÌåÔòÊôÓÚATPÁ¬ÏµºÐתÔËÌå (ATP binding cassette, ABC) ¼Ò×壬¿ÉʹÓÃË®½âATP µÄÄÜÁ¿¶ÔÒ©Îï¼°ÄÚÔ´ÐÔÎïÖʾÙÐÐתÔË£¬Ö÷Òª°üÀ¨P-ÌÇÂѰ×(P-glycoprotein, P-gp)¡¢¶àÒ©ÄÍÒ©Ïà¹ØÂÑ°× (multidrugresistance associated proteins, MRPs)¡¢ÈéÏÙ°©ÄÍÒ©ÂÑ°× (breast cancerresistance protein, BCRP) ¼°µ¨ËáÑÎÍâÅűÃ(bile salt export pump, BSEP)µÈ¡£
Ò©ÎïתÔËÌåµÄÓ¦ÓÃ
תÔËÌåÔÚÒ©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úл¼°ÉøÍ¸µÄ¶¯Á¦Ñ§Àú³ÌÖÐʩչÖ÷Òª×÷Óã¬Òò´ËÆä¹¦Ð§È±Ê§»òÒÖÖÆÊÇÒýÆðÒ©ÎïÏ໥×÷Óü°Ä³Ð©¼²²¡µÄÖ÷ÒªÔµ¹ÊÔÓÉ¡£ÏÖÔÚÐí¶àÒ©ÎïÒѱ»Ö¤ÊµÊÇתÔËÌåµÄµ×Îï»òÒÖÖÆ¼Á£¬Èç¶àÖÖ¿¹Ö×ÁöÒ©¡¢¿¹ÉúËØ¡¢Ç¿ÐÄÜÕÀà¡¢¸ÆÞ׿¹¼Á¡¢HIVÂѰ×øÒÖÖÆ¼Á¡¢ÃâÒßÒÖÖÆ¼ÁµÈµÄÌåÄÚÒ©¶¯Ñ§Àú³Ì¾ùÉæ¼°ÌØÒìµÄ»ò·ÇÌØÒìµÄתÔËÌ塣תÔËÌåÑо¿¶ÔÆÊÎöÒ©´ú¶¯Á¦Ñ§ÌØÕ÷¡¢Ò©Ð§Ñ§¼°¶¾ÐÔ¾ù¾ßÓÐÖ÷Òª×÷Óá£ÔÚÒ©ÎïÑз¢ÔçÆÚ¾ÙÐÐÒ©ÎïתÔËÌåÑо¿£¬¿ÉÒÔ¶Ô»¯ºÏÎïÔÚÈËÌåÄÚµÄÒ©´ú¶¯Á¦Ñ§²ÎÊý¾ÙÐÐÔçÆÚÕ¹Íû£¬¹ØÓÚÌá¸ßÁ¢ÒìÒ©ÎïµÄÑз¢Ð§ÂʾßÓÐÖ÷ÒªµÄÒâÒå¡£
×ðÁú¿Ê±ÊǽÏÔçÔÚÖйú¿ªÕ¹Ò©Îï´úл¶¯Á¦Ñ§Ð§À͵ÄCRO¹«Ë¾Ö®Ò»£¬Ð§ÀÍÁìÓòº¸Ç´úлÎȹÌÐÔ¡¢P450øÒÖÖÆ¡¢P450øÓÕµ¼¡¢Ã¸±íÐÍÆÊÎö¡¢ÂѰ×Á¬ÏµÂÊ¡¢ºìϸ°û/Ѫ½¬·ÖÅɱȡ¢Caco-2ÉøÍ¸ÐÔ¡¢×ªÔËÌåÑо¿¡¢´úл²úÆ·Åжϡ¢·´Ó¦ÐÔ´úл²úƷɸ²é¡¢ÖÖÖÖÊô¶à;¾¶¸øÒ©PK¡¢×éÖ¯ÂþÑÜÓëѪÄÔÆÁÕÏͨ͸ÐÔ¡¢ÉøÍ¸Ñо¿¡¢ÌåÄÚÒ©ÎïÏ໥×÷ÓᢶàÖÜÆÚ½»Ö¯BE¡¢´¦·½É¸Ñ¡µÈ¡£
ϸ»¯Ð§ÀÍÆ½Ì¨£¬ÓÅ»¯Ñз¢ÊÖÒÕ£¬ÍêÉÆÒ»Õ¾Ê½Ð§ÀÍ£¬×ðÁú¿Ê±×·Çó¸ü׿Խ£¬¸ü¾«×¼µÄÁÙ´²Ç°Ð§ÀÍ¡£
Ö÷Òª²Î¿¼ÎÄÏ×
[1] CFDA Ò©Îï·ÇÁÙ´²Ò©´ú¶¯Á¦Ñ§Ñо¿ÊÖÒÕÖ¸µ¼ÔÔò, 2015
[2] US FDGuidance for Industry£º Drug Interaction Studies¡ªStudy Design,Data Analysis, and Implications for Dosing and Labeling Recommendations £¨Draft Guidance£©£¬2012
[3] Àîñõ, Ê¢Àò, ÀîÑ࣬ҩѧѧ±¨,2014,49(7):963-970